A2

determining the interaction between the agent and the MAGE-A12 HLA binding peptide as a determination of the disorder.

A3

34.(amended) An isolated polypeptide which binds selectively a polypeptide of claim 1, provided that the isolated polypeptide is not an HLA molecule.

A4

42.(amended) A vaccine composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

A5

44.(amended) A vaccine composition comprising an antigen presenting cell of claim 40, and a pharmaceutically acceptable carrier.

Remarks

Applicants have canceled and amended claims to reduce the number of claims. No new matter has been added.

Respectfully submitted,

By: John R. Van Amsterdam

John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. L0461/7097
Dated: March 26, 2001
x03/26/01

Amended Claims

10.(amended) An isolated nucleic acid encoding a peptide selected from the group consisting of the peptide of [any of] claim[s] 1[-4], wherein the nucleic acid does not encode full length MAGE-A12.

19.(amended) A method for diagnosing a disorder characterized by expression of MAGE-A12 comprising:

contacting a biological sample isolated from a subject with an agent that is specific for a MAGE-A12 HLA binding peptide as claimed in claim 1, and

determining the interaction between the agent and the MAGE-A12 HLA binding peptide as a determination of the disorder.

34.(amended) An isolated polypeptide which binds selectively a polypeptide of [any of] claim[s] 1[-4], provided that the isolated polypeptide is not an HLA molecule.

42.(amended) A vaccine composition comprising the polypeptide of [any of] claim[s] 1[-4] and a pharmaceutically acceptable carrier.

44.(amended) A vaccine composition comprising [a cell selected from the group consisting of a T lymphocyte of claims 38 and 39 and] an antigen presenting cell of claim[s] 40 [and 41], and a pharmaceutically acceptable carrier.